Skip to main content
SpringerLink
Log in

Recurrent Clostridium difficile Infection

What are the Treatment Options?

  • Therapy in Practice
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Clostridium difficile infection (CDI) is an increasing problem in hospitalized patients. Recurrences of disease, despite the recommended treatments with metronidazole or vancomycin, are frequently seen and pose major problems for the clinical management of patients with CDI. Evidence for efficient clinical cure and low recurrence rates with primary use of alternative antibacterial treatment, such as fidaxomicin and rifaximin, is growing andthese treatment strategies need further exploration. The use of probiotics (e.g. Saccharomyces boulardii) may be considered, as well as combination therapy with vancomycin. Other promising therapies are the use of (monoclonal) antibodies and faecal transplantation, the efficacy of which has been suggested in smaller studies. Large studies evaluating faecal transplantation and other microbial products are underway. This article focuses on recurrent CDI and the possibilities for treatment and reduction of recurrence rates. Furthermore, general concepts of CDI and the primary treatment strategies are discussed. In summary, recurrent CDI remains a challenging clinical entity for which more treatment options will be forthcoming in the next few years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Pépin J, Routhier S, Gagnon S, et al. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006 Mar; 42(6): 758–64

    Article  PubMed  Google Scholar 

  2. Bauer M, Notermans D, van Benthem B, et al., ECDIS Study Group. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011 Jan; 377(9759): 63–73

    Article  PubMed  Google Scholar 

  3. Bouza E, Munoz P, Alonso R. Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin Microbiol Infect 2005 Jul; 11 Suppl. 4: 57–64

    Article  PubMed  Google Scholar 

  4. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997 May; 92(5): 739–50

    CAS  Google Scholar 

  5. Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007 Jul; (3): CD004610

  6. Bartlett J. Clinical practice: antibiotic-associated diarrhea. N Engl J Med 2002 Jan; 346(5): 334–9

    Article  PubMed  Google Scholar 

  7. Bricker E, Garg R, Nelson R, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2005 Jan; (1): CD004610

  8. Hu M, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009 Apr; 136(4): 1206–14

    Article  PubMed  Google Scholar 

  9. Kyne L, Farrell R, Kelly C. Clostridium difficile. Gastroenterol Clin North Am 2001 Sep; 30(3): 753–77

    Article  PubMed  CAS  Google Scholar 

  10. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001 Jan; 357(9251): 189–93

    Article  PubMed  CAS  Google Scholar 

  11. Moyenuddin M, Williamson J, Ohl C. Clostridium difficile-associated diarrhea: current strategies for diagnosis and therapy. Curr Gastroenterol Rep 2002 Aug; 4(4): 279–86

    Article  PubMed  Google Scholar 

  12. Musher DM, Logan N, Hamill R, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006 Aug; 43(4): 421–7

    Article  PubMed  CAS  Google Scholar 

  13. Pepin J, Alary M, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005 Jun; 40(11): 1591–7

    Article  PubMed  CAS  Google Scholar 

  14. McFarland L, Elmer G, Surawicz C. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002 Jul; 97(7): 1769–75

    Article  PubMed  CAS  Google Scholar 

  15. Best E, Fawley W, Parnell P, et al. The potential for airborne dispersal of Clostridium difficile from symptomatic patients. Clin Infect Dis 2010 Jun; 50(11): 1450–7

    Article  PubMed  Google Scholar 

  16. Roberts K, Smith C, Snelling A, et al. Aerial dissemination of Clostridium difficile spores. BMC Infect Dis 2008 Jan; 24(8): 7–12

    Article  Google Scholar 

  17. Donskey C. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004 Jul; 15(39): 219–26

    Article  Google Scholar 

  18. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000 Feb; 342(6): 390–7

    Article  PubMed  CAS  Google Scholar 

  19. McFarland L, Mulligan M, Kwok R, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989 Jan; 320(4): 204–10

    Article  PubMed  CAS  Google Scholar 

  20. Shim J, Johnson S, Samore M, et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998 Feb; 351(9103): 633–6

    Article  PubMed  CAS  Google Scholar 

  21. Bakken J. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009 Dec; 15(6): 285–9

    Article  PubMed  Google Scholar 

  22. Hopkins M, MacFarlane G. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol 2002 May; 51(5): 448–54

    PubMed  CAS  Google Scholar 

  23. McFarland L, Surawicz C, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999 Jan; 20(1): 43–50

    Article  PubMed  CAS  Google Scholar 

  24. Fekety R, MacFarland L, Surawicz C, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997 Mar; 24(3): 324–33

    Article  PubMed  CAS  Google Scholar 

  25. Loo V, Poirier L, Miller M, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005 Dec; 353(23): 2442–9

    Article  PubMed  CAS  Google Scholar 

  26. White H, Wiselka M. Inpatient mortality and death reporting associated with Clostridium difficile infection in a large teaching hospital. J Hosp Infect. Epub 2011 Feb 11

  27. Pépin J, Valiquette L, Gagnon S, et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007 Dec; 102(12): 2781–8

    Article  PubMed  Google Scholar 

  28. Zar F, Bakkanagari S, Moorthi K, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007 Aug; 45(3): 302–7

    Article  PubMed  CAS  Google Scholar 

  29. Gerding D. Treatment of Clostridium difficile-associated diarrhea and colitis. Curr Top Microbiol Immunol 2000; 250: 127–39

    PubMed  CAS  Google Scholar 

  30. Dubberke E, Reske K, Yan Y, et al. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007 Jun; 45(12): 1543–9

    Article  PubMed  Google Scholar 

  31. Owens Jr R, Donksey C, Gaynes R, et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008 Jan; 46 Suppl. 1: S19–31

    Article  PubMed  Google Scholar 

  32. Thomas C, Stevenson M, Riley T. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003 Jun; 51(6): 1339–50

    Article  PubMed  CAS  Google Scholar 

  33. Bignardi G. Risk factors for Clostridium difficile infection. J Hosp Infect 1998 Sep; 40(1): 1–15

    Article  PubMed  CAS  Google Scholar 

  34. Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003 Jul; 54(3): 243–5

    Article  PubMed  CAS  Google Scholar 

  35. Howell M, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010 May; 170(9): 784–90

    Article  PubMed  Google Scholar 

  36. Jung K, Park J, Chon Y, et al. Risk factors for treatment failure and recurrence after metronidazole treatment for clostridium difficile-associated diarrhea. Gut Liver 2010 Sep; 4(3): 332–7

    Article  PubMed  Google Scholar 

  37. Musher D, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005 Jun; 40(11): 1586–90

    Article  PubMed  CAS  Google Scholar 

  38. Cadena J, Thompson G, Patterson J, et al. Clinical predictors and risk factors for relapsing Clostridium difficile infection. Am J Med Sci 2010 Apr; 339(4): 350–5

    PubMed  Google Scholar 

  39. Garey K, Sethi S, Yadav Y, et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008 Dec; 70(4): 298–304

    Article  PubMed  CAS  Google Scholar 

  40. Johnson S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int J Antimicrob Agents 2009 Mar; 33 Suppl.: S33–6

    Article  PubMed  CAS  Google Scholar 

  41. McFarland L, Surawicz C, Greenberg R, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994 Jun; 271(24): 1913–8

    Article  PubMed  CAS  Google Scholar 

  42. Leung D, Kelly C, Boguniewicz M, et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991 Apr; 118 (4 Pt 1): 633–7

    Article  PubMed  CAS  Google Scholar 

  43. Warny M, Vaerman J, Avesani V, et al. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994 Feb; 62(2): 384–9

    PubMed  CAS  Google Scholar 

  44. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008 Nov; 47(9): 1162–70

    Article  PubMed  CAS  Google Scholar 

  45. Lamontagne F, Labbe A, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007 Feb; 245(2): 267–72

    Article  PubMed  Google Scholar 

  46. Louie T. How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile? CMAJ 2005 Oct; 173(9): 1049–50

    Article  PubMed  Google Scholar 

  47. McDonald L. Clostridium difficile: responding to a new threat from an old enemy. Infect Control Hosp Epidemiol 2005 Aug; 26(8): 672–5

    Article  PubMed  Google Scholar 

  48. Matamouros S, England P, Dupuy B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol 2007 Jun; 64(5): 1274–88

    Article  PubMed  CAS  Google Scholar 

  49. Goorhuis A, van Dissel J, Kuijper E. Novel risk factors for Clostridium difficile-associated disease in a setting of endemicity? Clin Infect Dis 2008 Dec; 47(3): 429–30

    Article  PubMed  Google Scholar 

  50. Norén T. Clostridium difficile and the disease it causes. Methods Mol Biol 2010; 646: 9–35

    PubMed  Google Scholar 

  51. Hecht D, Galang M, Sambol S, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007 Aug; 51(8): 2716–9

    Article  PubMed  CAS  Google Scholar 

  52. Bauer M, Kuiper E, van Dissel J, European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDAD). Clin Microbiol Infect 2009 Dec; 15(12): 1067–79

    Article  PubMed  CAS  Google Scholar 

  53. Cohen S, Gerding D, Johnson S, et al., Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010 May; 31(5): 431–55

    Article  PubMed  Google Scholar 

  54. Shah D, Dang M, Hasbun R, et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010 May; 8(5): 555–64

    Article  PubMed  CAS  Google Scholar 

  55. Apisarnthanarak A, Razavi B, Mundy L. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002 Sep; 35(6): 690–6

    Article  PubMed  Google Scholar 

  56. Louie T, Gerson M, Grimard D, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD) [abstract no. K-4259]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Washington (DC). Herndon (VA): American Society for Microbiology, 2007

  57. Al-Nassir W, Sethi A, Nerandzic M, et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008 Jul; 47(1): 56–62

    Article  PubMed  Google Scholar 

  58. Johnson S, Sanchez J, Gerding D. Metronidazole resistance in Clostridium difficile. Clin Infect Dis 2000 Aug; 31(2): 625–6

    Article  PubMed  CAS  Google Scholar 

  59. Peláez T, Alcala L, Alonso R, et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother 2005 Mar; 49(3): 1157–9

    Article  PubMed  CAS  Google Scholar 

  60. Baines S, O'Connor R, Freeman J, et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008 Nov; 62(5): 1046–52

    Article  PubMed  CAS  Google Scholar 

  61. Bolton R, Culshaw M. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986 Oct; 27(10): 1169–72

    Article  PubMed  CAS  Google Scholar 

  62. Friedenberg F, Fernandez A, Kaul V, et al. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 2001 Aug; 44(8): 1176–80

    Article  PubMed  CAS  Google Scholar 

  63. Bartlett J. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 2008 May; 46(10): 1489–92

    Article  PubMed  CAS  Google Scholar 

  64. Gonzales M, Pepin J, Frost E, et al. Faecal pharmaco-kinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis 2010 Dec; 10(363): 1–7

    Google Scholar 

  65. Kuipers E, Surawicz C. Clostridium difficile infection. Lancet 2008 May; 371(9623): 1486–8

    Article  PubMed  Google Scholar 

  66. Koo H, Garey K, Dupont H. Future novel therapeutic agents for Clostridium difficile infection. Expert Opin Investig Drugs 2010 Jul; 19(7): 825–36

    Article  PubMed  CAS  Google Scholar 

  67. de Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992 Oct; 36(10): 2192–6

    Article  PubMed  Google Scholar 

  68. Wenisch C, Parschalk B, Hasenhündl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996 May; 22(5): 813–8

    Article  PubMed  CAS  Google Scholar 

  69. Koo H, DuPont H. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gas-troenterol 2010 Jan; 26(1): 17–25

    Article  CAS  Google Scholar 

  70. O'Connor J, Galang M, Sambol S, et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2008 Aug; 52(8): 2813–7

    Article  PubMed  CAS  Google Scholar 

  71. Curry S, Marsh J, Shutt K, et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009 Feb; 15(48): 425–9

    Article  Google Scholar 

  72. Neff G, Zacharias V, Kaiser T, et al. Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: a case series. Liver Transpl 2010 Aug; 16(8): 960–3

    Article  PubMed  Google Scholar 

  73. Garey K, Jiang Z, Bellard A, et al. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol 2009 Jan; 43(1): 91–3

    Article  PubMed  Google Scholar 

  74. Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007 Mar; 44(6): 846–8

    Article  PubMed  CAS  Google Scholar 

  75. Johnson S, Schriever C, Patel U, et al. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009 Dec; 15(6): 290–1

    Article  PubMed  CAS  Google Scholar 

  76. Drekonja D. Rifampin plus metronidazole for Clostridium difficile infection [letter]. Infect Control Hosp Epidemiol 2010 Nov; 31(11): 1205; author reply 1205-6

    Article  PubMed  Google Scholar 

  77. Lagrotteria D, Holmes S, Smieja M, et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006 Sep; 43(5): 547–52

    Article  PubMed  CAS  Google Scholar 

  78. Jiang Z, DuPont H, LaRocco M, et al. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospitalin Houston, Texas. J Clin Pathol 2010 Apr; 63(4): 355–8

    Article  PubMed  CAS  Google Scholar 

  79. Herpers B, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009 Jun; 48(12): 1732–5

    Article  PubMed  CAS  Google Scholar 

  80. Lu C, Liu C, Liao C, et al. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole. Int J Antimicrob Agents 2010 Mar; 35(3): 311–2

    Article  PubMed  CAS  Google Scholar 

  81. Kopterides P, Papageorgiou C, Antoniadou A, et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care 2010 Jul; 38(4): 755–8

    PubMed  CAS  Google Scholar 

  82. US Food and Drug Administration. FDA Drug Safety Communication: increased risk of death with tygacil (tigecycline) compared to other antibiotics used to treat similar infections [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm [Accessed 2010 Dec 01]

  83. Anderson V, Curran M. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 2007; 67(13): 1947–67

    Article  PubMed  CAS  Google Scholar 

  84. Musher D, Logan N, Bressler A, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009 Feb; 48(4): e41–6

    Article  PubMed  CAS  Google Scholar 

  85. Musher D, Logan N, Mehendiratta V, et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007 Apr; 59(4): 705–10

    Article  PubMed  CAS  Google Scholar 

  86. Dudley M, McLaughlin J, Carrington G, et al. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea: a randomized double-blind trial. Arch Intern Med 1986 Jun; 146(6): 1101–4

    Article  PubMed  CAS  Google Scholar 

  87. Young G, Ward P, Bayley N, et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 1985 Nov; 89(5): 1038–45

    PubMed  CAS  Google Scholar 

  88. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 2004 Jul; 54(1): 211–6

    Article  PubMed  CAS  Google Scholar 

  89. Finegold S, Molitoris D, Vaisanen M, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004 Dec; 48(12): 4898–902

    Article  PubMed  CAS  Google Scholar 

  90. Louie T, Miller M, Donskey C, et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009 Jan; 53(1): 223–8

    Article  PubMed  CAS  Google Scholar 

  91. Miller M. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. Expert Opin Pharmacother 2010 Jun; 11(9): 1569–78

    Article  PubMed  CAS  Google Scholar 

  92. Miller M, Mullane K, Weiss K, et al. Faster time to resolution of diarrhea with fidaxomicin vs. vancomycin in patients with Clostridium difficile infection (CDAD) [poster no. 422]. 47th Annual Meeting of the Infectious Disease Society of America; 2009 Oct 29-Nov 1; Philadelphia (PA)

  93. Louie T, Miller M, Mullane K, et al., the OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011 Feb; 364(5): 422–31

    Article  PubMed  CAS  Google Scholar 

  94. Cornely O, Miller M, Louie T, et al. Randomized controlled trial (RCTt) of fidaxomicin (FDX) versus vancomycin (VAN) in treatment of recurrent Clostridium difficile infection (CDI) [abstract plus oral presentation]. 50th ICAAC; 2010 Sep 12–15; Boston (MA)

  95. Weiss K. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int J Antimicrob Agents 2009 Jan; 33(1): 4–7

    Article  PubMed  CAS  Google Scholar 

  96. Louie T, Gerson M, Grimard D, et al. Results of a phase III study comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD) [poster no. K-425a]. 47th ICAAC; 2007 Sep 17–20; Chicago (IL)

  97. Bouza E, Dryden M, Mohammed R, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in the treatment of Clostridium difficile-associated diarrhoea [abstract no. O464]. 18th ECCMID; 2008 Apr 19–22; Barcelona

  98. Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 1998; 66(5): 2018–25

    PubMed  CAS  Google Scholar 

  99. Lyerly DM, Bostwick EF, Binion SB, et al. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun 1991; 59(6): 2215–8

    PubMed  CAS  Google Scholar 

  100. van Dissel JT, de Groot N, Hensgens CM, et al. Bovine antibody enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: pre-clinical and preliminary clinical data. J Med Microbiol 2005; 54 (Pt 2): 197–205

    Article  PubMed  CAS  Google Scholar 

  101. Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis 2010 Dec 1; 51(11): 1306–13

    Article  PubMed  Google Scholar 

  102. Numan S, Veldkamp P, Kuijper E, et al. Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut 2007 Jun; 56(6): 888–9

    Article  PubMed  Google Scholar 

  103. Mattila E, Anttila V, Broas M, et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis 2008; 40(9): 702–8

    Article  PubMed  CAS  Google Scholar 

  104. Lowy I, Molrine D, Leav B, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010 Jan; 362(3): 197–205

    Article  PubMed  CAS  Google Scholar 

  105. Lee B, Popovich M, Tian Y, et al. The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine 2010 Jul; 28(32): 5245–53

    Article  PubMed  Google Scholar 

  106. Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005 Mar; 128(3): 764–70

    Google Scholar 

  107. O'Horo J, Safdar N. The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review. Int J Infect Dis 2009 Nov; 13: 663–7

    Article  PubMed  CAS  Google Scholar 

  108. McPherson S, Rees C, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006 May; 49(5): 640–5

    Article  PubMed  Google Scholar 

  109. Wilcox M. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004 May; 53(5): 882–4

    Article  PubMed  CAS  Google Scholar 

  110. Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008 Jan; (1): CD004611

  111. Wilson K. The microecology of Clostridium difficile. Clin Infect Dis 1993 Jun; 16 Suppl. 4: S214–8

    Article  PubMed  Google Scholar 

  112. D'Souza A, Rajkumar C, Cooke J, et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002; 324(7350): 1361

    Article  PubMed  Google Scholar 

  113. Lawrence S, Korzenik J, Mundy L. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005 Sep; 54 (Pt 9): 905–6

    Article  PubMed  Google Scholar 

  114. Surawicz C, MacFarland L, Greenberg R, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000 Oct; 31(4): 1012–7

    Article  PubMed  CAS  Google Scholar 

  115. Wullt M, Hagslatt M, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003; 35(6-7): 365–7

    Article  PubMed  Google Scholar 

  116. Lherm T, Monet C, Nougie`re B, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002 Jun; 28(6): 797–801

    Article  PubMed  Google Scholar 

  117. Muñoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005 Jun; 40(11): 1625–34

    Article  PubMed  Google Scholar 

  118. Garborg K, Waagsbo B, Stallemo A, et al. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis 2010 Dec; 42(11-12): 857–61

    Article  PubMed  Google Scholar 

  119. Aas J, Gessert C, Bakken J. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003 Mar; 36(5): 580–5

    Article  PubMed  Google Scholar 

  120. Jorup-Rönström C, Hakanson A, Persson A, et al. Feces culture successful therapy in Clostridium difficile diarrhea [in Swedish]. Lakartidningen 2006 Nov; 103(46): 3603–5

    PubMed  Google Scholar 

  121. Lund-Tønnesen S, Berstad A, Schreiner A, et al. Clostridium difficile-associated diarrhea treated with homologous feces [in Norwegian]. Tidsskr Nor Laegeforen 1998 Mar; 118(7): 1027–30

    PubMed  Google Scholar 

  122. Nieuwdorp M, van Nood E, Speelman P, et al. Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces [in Dutch]. Ned Tijdschr Geneeskd 2008 Aug; 152(35): 1927–32

    PubMed  CAS  Google Scholar 

  123. Persky S, Brandt L. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol 2000 Nov; 95(11): 3283–5

    PubMed  CAS  Google Scholar 

  124. Schwan A, Sjolin S, Trottestam U, et al. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis 1984; 16(2): 211–5

    Article  PubMed  CAS  Google Scholar 

  125. Silverman M, Davis I, Pillai D. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol 2010 May; 8(5): 471–3

    Article  PubMed  Google Scholar 

  126. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989 May; 1(8648): 1156–60

    Article  PubMed  CAS  Google Scholar 

  127. Borody T, Warren E, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003 Jul; 37(1): 42–7

    Article  PubMed  Google Scholar 

  128. Academic Medical Center. The FECAL trial, Fecal therapy to eliminate clostridium difficile associated longstanding diarrhoea. [Nederlands Trial Register number 1171]. Nederlands Trial Register [online]. Available from URL: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1177 [Accessed 2011 Apr 4]

Download references

Author information

Authors and Affiliations

  1. Departments of Internal Medicine, and Gastroenterology and Hepatology, Room Ba391, Erasmus MC University Medical Center, 's Gravendijkwal 230, 3015 CE, Rotterdam, the Netherlands

    Claire M. F. van Nispen tot Pannerden, Annelies Verbon &  Ernst J. Kuipers

  2. Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, the Netherlands

    Ernst J. Kuipers

Authors
  1. Claire M. F. van Nispen tot Pannerden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annelies Verbon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ernst J. Kuipers
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ernst J. Kuipers.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van Nispen tot Pannerden, C.M.F., Verbon, A. & Kuipers, E.J. Recurrent Clostridium difficile Infection. Drugs 71, 853–868 (2011). https://doi.org/10.2165/11591230-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11591230-000000000-00000

Keywords

Search

Navigation